SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following a clean double-beat earnings report, featuring record-breaking revenue and a significant $100 billion share buyback authorization. While some traders discuss potential volatility driven by supply chain constraints and the upcoming leadership transition, the community remains divided between those bullish on the company's capital return strategy and bears skeptical of the stock's valuation and growth trajectory.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending following a massive fiscal earnings beat and strong forward guidance that highlights sustained demand in the AI-driven data center storage sector. While the community is actively debating the sustainability of the stock's parabolic climb and the potential for a short-term sell-the-news correction, many investors remain focused on the company's pricing power and aggressive share buyback plans.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is currently experiencing intense retail-driven volatility and a massive short squeeze, fueled by an extremely low float and sky-high borrow fees. The community is sharply divided, with bulls betting on further parabolic gains to triple digits while skeptics warn of an imminent rug pull and long-term dilution risks.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened volatility ahead of earnings as investors debate its long-term cash burn against operational milestones like the start of R2 production. Community discourse is sharply divided between bulls focused on the R2's potential to scale production and skeptics who are concerned about executive compensation packages and the company's ongoing capital requirements.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following a massive earnings beat that sparked intense community debate over its long-term monetization potential and profitability. While bulls are highlighting the company's surging ad revenue and user engagement as catalysts for a potential breakout, skeptics remain wary of historical post-earnings volatility and broader sell-offs in the tech sector.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure as investors scrutinize the company's growth outlook, monetization challenges, and persistent safety concerns, leading to a sharp sentiment reset that has many traders monitoring key technical support levels. The community is actively debating the platform's long-term viability, with vocal arguments splitting between those betting on an oversold bounce and those wary of structural deceleration and platform-wide moderation risks.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing significant market volatility and high trading volume following the announcement of a multi-million dollar milestone payment from their collaboration with Boehringer Ingelheim. Community sentiment remains polarized, with many traders closely monitoring the potential for a reverse stock split, while others are optimistic that the company's progress in autoimmune research and pending clinical trial milestones could drive a sustained rebound.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following a significant quarterly earnings beat that surpassed analyst expectations for both revenue and EPS, signaling to investors that enterprise demand remains durable. The community is actively debating whether this performance marks a structural turnaround for the software sector or a temporary relief bounce, while discussions remain polarized over the long-term impact of AI on SaaS business models.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending as traders closely monitor volatility in the memory sector, sparked by the company's strong earnings beat and subsequent market pullback. The community remains divided, with bulls pointing to robust AI-driven storage demand and long-term infrastructure growth, while bears are debating whether current valuation levels are overextended and susceptible to distribution.

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

iSpecimen Inc. is attracting attention as traders track its low float and potential for volatility, with community sentiment divided between those anticipating a parabolic short squeeze and those skeptical due to ongoing downward price pressure and reverse split concerns. Speculation continues to swirl around possible strategic acquisitions or corporate news, keeping the ticker highly active despite the lack of official catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recomme...

Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Friday...

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research...

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...

What is HC Wainwright's Estimate for COYA Q1 Earnings?

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Coya Therapeutics in a note issued to investors...

Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Monday...

Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Chardan Capital restated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Monday...

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Current Price	$4.23
Prev Close	$4.07
Open	$4.11
Dividend Yield	0.00%
50-Day Moving Average	$4.47
Beta	1.05
Avg. Volume	138,453.83
PE Ratio	-3.52

52-Week High	$7.75
52-Week Low	$3.71
Market Capitalization	$95.47M
EPS (Annual)	-$1.27
Price to Book	2.06
Revenue Per Employee	$993,219.13

COYA
Coya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest COYA News

COYACoya Therapeutics Inc